Using an ordinal measure of cutaneous sensitivity to intradermal injections of atracurium and vecuronium, 40 nonreacting subjects were compared with a group of 24 patients previously suffering life-threatening anaphylactoid reactions to other muscle relaxants. Enhanced cutaneous sensitivity to vecuronium was found in three, and to atracurium in two of the previously reacting group. With the exception of those showing abnormal reactivity, no significant difference was found in the distribution of cutaneous sensitivity in the control and reacting group. A concentration of vecuronium 8.75 times that of atracurium was required to produce an equivalent intradermal wheal response.
Anaphylactoid
reactions to the neuromuscular blocking agents are common, clinical symptoms varying from mild cutaneous erythema to major life-threatening cardiovascular collapse and/or bronchospasm. I In some cases classical laboratory evidence of Type I hypersensitivity (i.e. anaphylaxis) is found and these patients usually demonstrate exquisite intradermal sensitivity to the injection of dilute relaxant solutions2,3,4. Such intradermal sensitivity is shown at dilutions greater than those producing typical wheal-andflare responses in normal individuals.
Intradermal cross-sensitivity is found between the commonly used muscle relaxants 5 • We have observed this particularly between ·F suxamethonium, gallamine, d-tubocurarine and alcuronium, with cross-sensitivity between these agents and pancuronium being less common.
Two newer muscle relaxants have recently been introduced into anaesthesia; atracurium, a novel bisquaternary competitive neuromuscular blocker, and vecuronium, a monoquaternary homologue of pancuronium 6 • The purpose of this study was to examine intradermal sensitivity to these agents in a group of patients with known hypersensitivity to other neuromuscular blockers.
PATIENTS AND METHOD An initial group of four nonreacting volunteers was selected for a pilot study to determine the normal cutaneous response to intradermal challenge of atracurium and vecuronium. This group was combined with a further 36 nonreacting subjects to establish control values for normal subjects. Comparison was then made with a group of 24 patients with a history of life-threatening anaphylactoid reactions to muscle relaxants none of whom had been previously exposed to vecuronium or atracurium.
Pilot Study
Solutions of atracurium and vecuronium in 0.9070 saline were freshly prepared before each testing session to achieve final drug concentrations given in Table I . The volar aspect of each forearm was prepared with isopropyl alcohol. Intradermal injections were made at 3cm intervals along the medial and lateral borders beginning with the highest concentration 3cm below the elbow crease. Atracurium was injected into the right and vecuronium into the left forearm. All injections were made with a Iml tuberculin syringe and 30swg needle. 0.02ml was injected at each site. In addition to the test drugs, a control injection of 0.9070 saline was given to rule out dermatographia.
After fifteen minutes the injection sites were examined and the outline of any observable wheal was marked on the skin using a fine ink pen. Strips of clear adhesive plaster were used to remove the outlines and, when affixed to Imm ruled graph paper, provided a permanent record.
At each dilution the mean wheal diameter was calculated from wheal area, obtained by the method of counting squares.
Control Group
Thirty-six nonreacting volunteers were given intradermal testing to four serial log concentrations (Table I) . Mean wheal diameters were calculated by taking the average of the maximum diameter and the perpendicular diameter at the midpoint of this maximum diameter.
Previously Reacting Group
All reacting patients were first given intradermal testing to the drugs to which they had previously reacted. This was carried out according to a standard protocol with 0.02ml injections of the appropriately diluted reacting drugs. The criteria for a positive skin test was a wheal diameter of greater than Icm as described by Fisher 7 • 8 • If sensitivity was confirmed then injections of the test drugs were given. Reacting patients were tested in a similar fashion to the control group but with testing beginning at the lowest concentrations and increasing until a wheal of 15mm was produced or until the undiluted drug had been given.
Anaesthesia and Intensive Care, Vol. 13, No. 3, August, 1985 Further dilutions were made as required to determine the lowest concentration producing a wheal-and-flare response equal to that of the control saline. Injection sites in the reacting and nonreacting groups were comparable for each drug and concentration.
RESULTS
For each subject and drug, the wheal diameter was plotted against log concentration and for diameters over 4mm, the smallest easily measured diameter, these plots were found to be approximately linear with the mean Pearson correlation coefficient (rc) equal to 0.97 for atracurium and 0.92 for vecuronium ( Figure 1) .
The linear nature of these dose/response curves for, presumably, direct histamine release is similar to that found for immunologically mediated intradermal reactions to allergens 9 • A measure of a patient's sensitivity to an allergen or direct histamine-releasing drug can be expressed by the position of the log dose/response curve along the log concentration axis. Such a measure does not presuppose a mechanism of intradermal sensitivity but rather quantitates its degree.
In order to represent the position of each dose/response curve, we calculated a linear regression equation for each curve and selecting a 7mm wheal diameter as a standard, extrapolated the log concentration required to give this wheal diameter. This extrapolated log concentration was then used as an ordinal measure of cutaneous sensitivity to the test drugs. Thus, in this discussion the cutaneous sensitivity of a drug is defined as the 10glO of the concentration required to produce a wheal diameter of 7mm when injected intradermally in a volume of 0.02ml. The values of cutaneous sensitivity were calculated for the control and previously reacting patients.
Mean wheal diameters and mean regression lines for the control subjects are shown in Figure 2 and set out in detail in Table 2 . Regression slopes for atracurium and vecuronium were similar and at the 7mm end point represented a separation of 0.95 logs or an 8.75 fold difference in concentration required to give a similar wheal diameter. Figures 3 and 4 show the distribution of cutaneous sensitivity to the two drugs in the control and reacting groups. The cutoff point for abnormal values of cutaneous sensitivity in the reactors has been taken, in this discussion, as the upper limit of the range of controls.
In the previously reacting group, two subjects were found to have abnormally increased values of cutaneous sensitivity to atracurium and three to vecuronium. Both of those with increased cutaneous sensitivity to atracurium also gave abnormal values to vecuronium. Table 3 shows the incidence of cross reactivity between these drugs and the other muscle relaxants to which these patients have been tested. The frequency is represented as the number of patients demonstrating enhanced sensitivity to both agents divided by the total number of patients with increased reactivity to either agent. Although numbers are small, this data may suggest cross-reactivity between pancuronium and vecuronium, and atracurium and vecuronium.
When the three patients showing increased sensitivity to the test drugs are excluded from comparison, no significant difference is found between the cutaneous sensitivity of controls or reactors using non-parametric analysis (Mann-Whitney U-test atracurium p<O.9 vecuronium p<O.5), DISCUSSION Atracurium and vecuronium are two recently introduced neuromuscular blocking agents which have been shown to produce little direct histamine release in clinically used doses. 7 Our own data suggests that atracurium has 8.75 times the cutaneous histamine releasing potential of vecuronium. As atracurium is used in doses four times greater than vecuronium muscular blockade, it is suggested that vecuronium is preferable for those patients at risk from histamine, e.g. those with increased bronchial reactivity. Some caution must be observed, however, in equating dermal reactivity to that of other organ systems.
Using an ordinal measure of cutaneous sensitivity we have demonstrated a number of patients, previously reacting to other muscle relaxants, with enhanced sensitivity to atracurium and/or vecuronium. However, unless specific sensitivity was found, previously reacting patients did not differ in their cutaneous sensitivity to these muscle relaxants from normal subjects. This implication of drug-specific sensitivity is consistent with an immunological mechanism rather than an idiosyncratic abnormality of histamine release or effect as has been suggested by some authors. I
The number of patients cross-reacting to vecuronium or atracurium is low. Although there is a significant difference in their direct histamine-releasing potential, immunologically they may both represent an improvement over the older relaxants, with the exception of perhaps pancuronium.
Cross-sensitivity was found particularly between atracurium, vecuronium and pancuronium. Although valid conclusions cannot be made because of the small numbers, the chemical similarity of vecuronium and pancuronium is again consistent with immunological cross-reactivity.
In the diagnosis of intraoperative anaphylactoid reactions, skin testing is of demonstrated value. lo Fisher has based his criteria for positivity of these tests on single injections of a fixed dilution and wheal diameters of greater than 1.0 cm. 8 Using this technique we have found considerable difficulty in interpreting those patients with wheal diameters close to this absolute limit. While such patients must be interpreted in the light of their clinical history and other relevant investigations, an ordinal measure of skin sensitivity, such as that described, allows individual sensitivities to be graded and the potentially misleading classification of patients as positive or negative may be avoided. It is possible that cutaneous sensitivity could be expressed in terms of the deviation from the normal control mean and, since the standard deviation of the cutaneous sensitivity for both drugs in the control groups was found to be similar, the statistical z score might be an appropriate measure of sensitivity.
In retrospect, we believe that while the method of measuring cutaneous sensitivity described was useful in enabling discrimination between hypersensitive from normal patients, several criticisms can be made. First, our choice of tenfold increments in drug dilutions for the control group was too broad and may have obscured significant flattening of the dose/response curves at the upper and lower ends of drug concentration. Secondly, intradermal sites where no wheal was visible were counted as zero wheal diameters, and these tended to lower the overall mean wheal diameter and hence the value of cutaneous sensitivity. We are currently obtaining normal control values for all common neuromuscular blockers taking into account these problems.
For the nondepolarising muscle relaxants, the interpretation of intradermal skin test results has been claimed to be unreliable because of interference by direct histamine release. 11 Some patients show, however, intradermal responses at dilutions greater than those in normal controls. The use of cutaneous sensitivity allows statistical comparison of wheal responses between individuals and, although giving no indication as to the mechanism involved, is suggested as a useful measure when testing drugs known to be direct histamine releasers.
